Stay updated with breaking news from Edwin Rock. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Operator: Good morning, and thank you for joining the GlycoMimetics Q4 and Full Year 2023 Earnings Call. At this time, all participants are in a listen-only mode.
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today announced the 65th American Society of Hematology (ASH) Annual Meeting will feature two presentations o...
GlycoMimetics, Inc. , a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today announced the 65th American...
GlycoMimetics, Inc. (NASDAQ:GLYC – Get Free Report) shares passed above its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of $1.36 and traded as high as $1.53. GlycoMimetics shares last traded at $1.53, with a volume of 79,729 shares. Analyst Ratings Changes Several research analysts recently weighed in […]
Operator: Good morning, and thank you for joining the GlycoMimetics Q3 2023 Earnings Call. At this time, all participants are in a listen-only mode.